Bacillus anthracis infections – new possibilities of treatment
Dorota Żakowska 1, Michał Bartoszcze 1, Marcin Niemcewicz 1, Agata Bielawska-Drózd 1, Józef Knap 2, Piotr Cieślik 3, Krzysztof Chomiczewski 4, Janusz Kocik 5 1 - Biological Threats Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Puławy, Poland 2 - Warsaw Medical University, Department of Epidemiology, Institute of Social Medicine, Warsaw, Poland 3 - Biological Threats Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Puławy, Poland 4 - Faculty of Chemistry and New Techonlogies, Military University of Technology, Warsaw, Poland 5 - Military Institute of Hygiene and Epidemiology, Warsaw, Poland Ann Agric Environ Med 2015; 22 (2): ICID: 1152065 Article type: Review article
Introduction and objective. Bacillus anthracis is one of biological agents which may be used in bioterrorism attacks. The aim of this study a review of the new treatment possibilities of anthrax, with particular emphasis on the treatment of pulmonary anthrax. Abbreviated description of the state of knowledge. Pulmonary anthrax, as the most dangerous clinical form of the disease, is also extremely difficult to treat. Recently, considerable progress in finding new drugs and suitable therapy for anthrax has been achieved, for example, new antibiotics worth to mentioning, levofloxacin, daptomycin, gatifloxacin and dalbavancin. However, alternative therapeutic options should also be considered, among them the antimicrobial peptides, characterized by lack of inducible mechanisms of pathogen resistance. Very promising research considers bacteriophages lytic enzymes against selected bacteria species, including antibiotic-resistant strains. Results. Interesting results were obtained using monoclonal antibodies: raxibacumab, cAb29 or cocktails of antibodies. The application of CpG oligodeoxynucleotides to boost the immune response elicited by Anthrax Vaccine Adsorbed and CMG2 protein complexes, also produced satisfying therapy results. Furthermore, the IFN-α and IFN-β, PA-dominant negative mutant, human inter-alpha inhibitor proteins and LF inhibitors in combination with ciprofloxacin, also showed very promising results. Conclusions. Recently, progress has been achieved in inhalation anthrax treatment. The most promising new possibilities include: new antibiotics, peptides and bacteriophages enzymes, monoclonal antibodies, antigen PA mutants, and inter alpha inhibitors applications. In the case of the possibility of bioterrorist attacks, the examination of inhalation anthrax treatment should be intensively continued.
DOI: 10.5604/12321966.1152065 PMID 26094508 - click here to show this article in PubMed